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Abstract 
BACKGROUND: Filgrastim, a neopogen brand, is a blood-forming agent and a natural protein in the body that 
plays a role in stimulating the growth of white blood cells and protecting them against infectious agents. To the 
best of knowledge, human and animal specimens have shown the effect of Filgrastim on treating brain injuries 
regarding bone marrow transfusion into the blood, neuroprotection, stimulation of neurons for forming new neural 
networks and reducing the risk of bacterial infections.  
AIM: This study aimed to investigate the effect of Filgrastim on the prognosis of a cerebral haemorrhage in 
patients with traumatic brain injury. 
METHODS: This study was conducted as a clinical trial, in which the initial diagnosis of patients with cerebral 
haemorrhage due to head trauma was performed with a clinical examination and CT scan. After the patient 
arrives at the emergency room, the patient's initial examination is performed, and blood tests are taken from the 
patient. Moreover, CBC values (Hb, Platelet, Hematocrit) were checked and recorded in the checklist. The 
intervention group received 150 mcg/day Filgrastim injected subcutaneously for 4 days. Furthermore, patients in 
the control group received the same amount of sterile water. At the end of the treatment period, blood tests were 
performed again in all patients, and their results were then recorded. All data were analysed by SPSS v.21 
software package.  
RESULTS: Our findings revealed that the mean volume of bleeding in the intervention group based on CT scan 
was significantly reduced after four days as compared to the control group. Moreover, the mean score of 
consciousness and muscular strength of patients in the intervention group was significantly higher than the control 
group. Also, WBCs in the intervention group exhibited a significant increase after four days of intervention, while 
platelet and hematocrit levels in the intervention group decreased significantly compared to the control group. 
CONCLUSION: Regarding the results, the therapeutic application of filtration is considered to be effective. Given 
the lack of serious complications of the proposed dosages, the use of this drug can be suggested. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Brain trauma and its complications, such as 
cerebral haemorrhage results from a blow or jolt to the 
head and have led to the loss of high-yielding years in 
the community, which is a leading cause of mortality. 
Traumatic brain injury is one of the key factors in 
public health, where is considered to be one of the 
most important causes of death among young people 
in rich countries.  
Given the growing growth of motor vehicles, 
the rate of brain injury in the world is increasing. It is 
estimated that more than 10 million brain injury occurs 
annually worldwide in need of hospital care. It is worth 
noting that 9% of all deaths in the world are due to 
traumatic brain injury. Surviving patients are likely to 
be affected by permanent or temporary disabilities. 
The financial burden of traumatic brain injury has 
been estimated to be more than $ 60 billion annually 
(only in the United States). Many traumatic brain 
damage develops during hospitalisation and increases 
the need for surgery or the degree of complications 
and mortality of patients [1]. Trauma is the most 
common cause of death for people ages 1 to 44 
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years. Head trauma is the most common cause of 
hospitalisation and death of traumatic patients (40 to 
50%), [2]. The traumatic brain haemorrhages are 
divided into delayed and early traumatic intracerebral 
haemorrhages. Early haemorrhages are related to 
patients who have been diagnosed with haemorrhage 
in a CT scan for up to six hours after the trauma. 
However, haemorrhage is likely to appear after 6 
hours with CT scans for various reasons, where such 
haemorrhage is called delayed intracerebral 
haemorrhage. Delayed traumatic intracerebral 
hematoma (DTICH) is one of the most important 
treatable complications of secondary brain damage in 
patients with brain trauma [3].  
Since CT scan has become commonplace as 
a good diagnostic tool, the DTICH incidence in all 
patients with brain damage is reported to be between 
0.6% and 7.4%. DTICH can include all kinds of 
cerebral haemorrhages, including intraparenchymal 
haemorrhage (IPH), subdural haemorrhage (SDH), 
and extradural haemorrhage (EDH) or epidural 
haemorrhage (EDH). Although DTICH may be present 
in a patient who has already had a history of brain 
damage, it can occur in patients with primary normal 
CT scan results. The death rate for DTICH is more 
than 35% to 40% [2]. Nevertheless, various studies 
have shown that mortality rates are significantly 
reduced in the event of timely diagnosis and rapid 
treatment [3]. In the absence of timely diagnosis and 
treatment, the mortality rate may even be higher than 
50% [4]. Studies show that DTICH can occur in each 
age group with varying degrees of trauma and with 
different levels of patient alertness, even in patients 
with GCS of 15, as well as patients with a completely 
normal CT scan or without a skull fracture [5].  
Granulocyte colony stimulator (G-CSF) is a 
glycoprotein that generates a hematopoietic cell 
colony in the culture of bone marrow cells. G-CSF is 
an important factor in neutrophil-based immune 
defence system due to a regulatory role in growth, 
differentiation, survival and activation of neutrophils 
and precursors [6]. 
 Filgrastim is a blood-forming agent and a 
natural protein called Neupogen, which stimulates the 
growth of white blood cells in the body and protects 
these cells against infection. Filgrastim is used for 
several therapeutic purposes, including neutropenia, 
the loss of some white blood cells from cancer, bone 
marrow transplantation, chemotherapy, or other 
conditions. Filgrastim is considered to be the synthetic 
form of G-CSF (Granulocyte Stimulator), a natural 
protein that promotes the production of white blood 
cell production. It should be taken into consideration 
that G-CSF deficiency increases the risk of bacterial 
infections.  
This drug induces bone marrow to produce 
white blood cells and thereby reduce the risk of 
infection. Therefore, bone marrow cells enter the 
bloodstream to make bone marrow transplantation 
easy [7]. Recent studies on human and animal 
specimens have revealed the effect of filgrastim on 
the treatment of brain injuries for several functions, 
such as the entrance of bone marrow cells into the 
blood, neuroprotection, stimulation of neural cells for 
forming new neural networks and reducing the risk of 
bacterial infections [2] [8]. 
Despite extensive research in recent years, 
there is still no drug that can protect against the 
effects of brain damage and subsequent bleeding 
from brain cells. Therefore, this study aimed to 
investigate the effect of Filgrastim on the prognosis of 
a cerebral haemorrhage in patients with traumatic 
brain injury. 
 
 
Material and Methods 
 
This randomised, double-blind clinical study 
was conducted among patients referred to the 
emergency department of Vali-e-Asr Hospital in Arak 
for head trauma. Patients were selected based on the 
initial diagnosis with a clinical examination and CT 
scan. All patients with inclusion criteria were entered 
into intervention and control groups at the time of 
arrival using a random number table. After the 
patient's arrival, the patient's primary examination was 
performed and the patient's background information, 
including age, sex, and the cause of the trauma, were 
recorded. Blood tests were performed from patients, 
and the complete blood count (CBC) (Hct and PLt, 
Hb) were checked and recorded on the checklist. 
Patients in the case group (34 patients) received a 
subcutaneous injection of 150 mg Filgrastim weekly 
for 4 days. Before and during treatment with this drug, 
vital signs, haemoglobin and electrolytes were 
carefully checked. 
On the other hand, patients in the control 
group (34 patients) received the same amount of 
distilled water. It should be noted that the patient was 
not aware of the type of treatment received. Patients 
were monitored for the type of brain injury, CBC, vital 
signs, and coagulation tests, as well as some 
electrolytes. At the end of the course of treatment, 
blood tests were repeated in all patients. If the 
laboratory factors were normal, response to the 
treatment was recorded for patients.  
Finally, the data were analysed by SPSS v.21 
software using SPSS software. To evaluate the 
results, indicators such as mean, standard deviation, 
standard error, frequency percentage were employed. 
For analytical analysis, the covariance test, Chi-div 
test and Independent T-test or its nonparametric 
equivalents were used to compare the mean. 
Meanwhile, values of p < 0.05 were considered as 
significant levels. 
Entry criteria included: 1) aged 18 years and 
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above; 2) patients with head trauma, 3) 
consciousness (GCS) between 9 and 13; 4) Filling out 
the informed consent. 
Exclusion criteria included: 1) Inclination to 
participate in the study; 2) Alcohol, and drug use, or 
any factor other than brain trauma that reduces the 
level of consciousness in the patient; 3) Acute 
hypersensitivity to the drug; 4) history of hypertension, 
diabetes, embolism and DVT; 5) Alertness below 9 
and above 13; 6) Patient's death 72 hours after 
entering the emergency room. 
In all stages of the project, ethical 
considerations such as informed consent for 
participating in the study and withdrawal were 
voluntarily, and the confidentiality of the information 
was observed. This research project was approved by 
the ethical committee of Arak University of Medical 
Sciences (No. 1173 and the code of ethics: 
IR.ARAKMU.REC.1395.100). 
 
 
Results 
 
Most of the patients in the experimental group 
(76.7%) were male, and the remaining was female. 
Furthermore, most of the patients in the control group 
(83%) belonged to men and 17% of the remaining 
was women. To examine the homogeneity of the two 
groups, the Chi-square test was applied. The findings 
revealed that there was no significant difference in sex 
between the two groups (P = 0.22). In the test group, 
the majority of patients (46.6%) were in the age group 
of 21-30 years and the lowest (10%) in the age group 
of 20 to 20 years old. Furthermore, most of the 
patients in the control group (50%) were in the age 
group 40, and the lowest (6%) belonged to the age 
group of 40-31 years old (Figure 1).  
 
Figure 1: Age distribution in the intervention and control group 
 
It should be taken in to account that the 
Fisher test was employed to check the homogeneity 
of the two groups. Based on the results, there was no 
significant difference between the two groups 
regarding age (P = 0.42). Chi-square test exhibited no 
significant difference regarding height and weight 
between the two groups (Table 1). 
Table 1: Frequency distribution of patients in two groups of 
intervention and control regarding height and weight 
Sex Height Weight 
Intervention 98.01  ±23.011 32.00  ±81.23 
Control 55.01  ±3.019 59.01  ±2.23 
P –value 1.591 1.331 
 
Based on the results of t-test presented here, 
the level of consciousness of both groups did not 
show any significant difference (P = 0.65) and also 
after the intervention, no significant difference was 
found in consciousness level of both groups (P = 0.05) 
based on the use of t-test (Table 2). 
 
Table 2: Frequency distribution of patients in two groups of 
intervention and control regarding the level of consciousness 
GCS Intervention controls P –value 
GCS0 03.0  ±91.01 01.0  ±21.01 1.151 
GCS4 33.0  ±51.00 33.0  ±21.01 1.15 
 
The t-test demonstrated that the mean scores 
of vital signs before and after intervention in both 
groups were not statistically significant (P > 0.05; 
Table 3). 
Table 3: Frequency distribution of patients in two groups of 
intervention and control regarding vital signs 
Variables  Intervention Control T-test P-value 
SBP before 
intervention 
2.22  ±2.021 30.03  ±03.022 1.051 
SBP after intervention 08.9  ±32.023 21.8  ±1.023 1.321 
DBP before 
intervention 
82.1  ±82.22 30.2  ±21.90 1.221 
DBP after intervention 33.5  ±01.25 29.1  ±91.25 1.281 
PR before intervention 55.5  ±32.011 9.5  ±12.83 1.211 
PR after intervention 81.5  ±21.821 31.1  ±31.81 1.201 
RR before intervention ½  ±3.09 02.3  ±0.08 1.991 
RR after intervention 80 . ±2.02 0.0  ±8.01 1.291 
T before intervention 21 . ±0.22 2 . ±19.22 1.291 
T after intervention 2 . ±0.22 22 . ±0.22 1.551 
 
As shown in Table 4, the mean scores of 
hospitalisation days in both groups were statistically 
significant (P = 0.000). 
Table 4: Distribution of hospitalisation days in two groups of 
intervention and control 
Variable Intervention Control Test 
hospitalisation days 81. 1±2 23.0±52.8 1.111 
 
Based on the data presented in Table 5, 
independent t-test indicated no significant difference 
regarding the mean blood volume in both groups (P = 
0.3), while it was statistically significant after four days 
(P = 0.000). 
Table 5: Computed tomography from the first to fourth days 
Variable Intervention (cm3) Control (cm3) T-test P-value 
Scan the first day 53.3±92.03 82.3±51.05 1.112 
Scan the second day 99.0±93.01 91.0±11.03 1.111 
Scan the third day 22.0±21.8 21.0±11.02 1.111 
Scan the fourth day 91.±11.2 58.0±11.00 1.111 
 
Moreover, we found that the mean of muscle 
strength of the first day was not statistically different in 
both groups (P = 0.3), while its values were 
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statistically significant after four days in two groups (P 
= 0.000) (Table 6). 
Table 6: Muscle strength on days 1 to 4 in both groups 
Variable Intervention Control T-test P-value 
Muscle strength the first day  20.1±3.0 51.1±31.3 0.300 
Muscle strength the second day  10.1±21.3 52.1±21.3 0.06 
Muscle strength the third day  22.1±31.2 15.1±21.3 0.30 
Muscle strength the fourth day 91.1±2.2 55.1±81.3 0.005 
 
The mean of HCT, WBC and PLT in both 
groups did not show a significant difference by t-test 
before the intervention (P > 0.05), while the mean 
values of these variables in both groups were not 
significantly different after four days of intervention (P 
>0.05) (Table 7). 
Table 7: Frequency distribution of CBC in the control and 
intervention groups 
Variable Intervention Control T-test P-value 
Hematocrit before intervention 29.2±21.32 53.2±53.33 0.30 
Hematocrit after intervention 30.3±92.30 20.2±31.35 0.10 
WBC before intervention 30.3±85.01 11.0±92.01 0.90 
WBC after intervention 33.3±21.31 28.2±51.05 0.000 
Platelet before intervention 32.92±32.213 15.20±52.385 0.080 
Platelet after intervention 53.92±52.330 98.95±32.211 0.020 
 
Based on t-test, mean PT and PTT before 
and after intervention were not significantly different in 
both groups) P > 0.05; Table 8(. However, after four 
days of intervention, mean PT in both intervention and 
control groups exhibited a significant difference (P < 
0.05). Where the PTT coagulation test did not show a 
significant difference after four days, as a comparison 
of the two groups (P = 0.4). 
Table 8: Frequency distribution of patients in two groups of 
intervention and control according to coagulation tests 
Variable Intervention Control T-test P-value 
PT before intervention 82. 3±2.02 53.3±8.03 0.09 
PT after intervention 81.3±12.05 81.±12.01 0.05 
PTT before intervention 35.3±02.31 15.0±02.31 0.01 
PTT after intervention 92.±21.31 12.0±02.31 0.04 
 
 
 
Discussion 
 
This study aimed to investigate the effects of 
filgrastim on the complications of patients with a head 
traumatic brain haemorrhage. The present study 
showed that the majority of patients in the intervention 
group (46.6%) were in the age group of 21-30 years 
old and the lowest number of patients (10%) was in 
the age group of 10 to 20 years old.  
In the control group, the majority of patients 
(50%) were in the 40-year-old age group, while fewer 
patients (6%) were in the age group of 31-40 years... 
According to the results presented in this 
study, most of the patients (76.7%) belonged to men. 
These statistics vary in different societies, but the 
most common age group with traumatic brain injury 
has been reported to be between 20-29 years old in 
most countries, including Taiwan. In concurring with 
the present study, various international and regional 
studies have reported that the prevalence of head 
injuries in men was higher than in women [9]. 
The results of the current study demonstrated 
that the level of consciousness in both groups was not 
significantly different on the first day; however, after 4 
days of administration, the level of consciousness in 
the intervention group based on Glasgow criteria was 
significantly higher than that of the control group. 
To the best of our knowledge, a similar study 
was not found on the effects of filgrastim and 
consciousness levels, but Zareian et al., have 
revealed that using Epigallocatechin-3-gallate over 7 
days has been able to increase the level of 
consciousness in the intervention group compared to 
the control group, which is consistent with our study 
[10]. Furthermore, our findings emphasised that the 
number of hospital admissions days in the intervention 
group was significantly lower than those in the control 
group. One of the important issues that have always 
been addressed by the managers of hospitals and 
health centres is the length of stay that is both 
economically and organizationally important. 
The length of hospitalisation can be employed 
as a factor in assessing the efficiency and 
effectiveness of hospital services. These criteria can 
be applied for various purposes such as healthcare 
management, quality control of hospital services [11]. 
It should be noted that the use of filtration in 
controlling the complications of head trauma patients 
has been able to reduce the length of hospitalisation. 
The location, volume of bleeding and the amount of 
pressure on the brain tissue are important factors for 
hematoma. CT scan is a tool that, in addition to being 
able to perform in emergency situations, has the 
ability to detect the exact location of the hematoma, 
the volume of the hematoma, and the amount of 
pressure on one part of the brain (shifts), so it is very 
helpful in determining the therapeutic strategies. To 
diagnosis the volume of hematoma, Epperson and 
Peterson criteria can be employed, which is found by 
multiplying the length, width and height of the 
hematoma in 0.5 [12]. Based on the results presented 
here, using filgrastim drug significantly reduced the 
volume of bleeding in CT scan on days 3 and 4, as 
compared to the patients in the control group. In other 
words, filgrastim has been able to reduce the volume 
of bleeding in patients with a brain hemorrhage, when 
comparing with the control group. Shabiri et al. 
measured the hemorrhage volumes on CT in the 
bleeding trauma patients, concluding that reducing the 
volume of cerebral hemorrhage is associated with an 
increase in the level of consciousness [13], which is 
consistent with our study outcomes. In addition, the 
results of this study revealed that the patients in both 
groups did not differ in muscle strength before the 
study, but the mean scores of muscle strength 
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increased significantly in the intervention group after 
four days of using filgrastim. Studies have 
emphasised that lower levels of brain injury and 
bleeding complications could be linked to an increase 
in muscle strength, which is directly related to the 
patient's level of consciousness [14]. 
Moreover, our findings suggested that after 
four days of taking filgrastim, the hematocrit levels, 
platelet counts in the intervention group were lower 
than the control group, were showed a statistically 
significant difference. Nevertheless, WBCs in the 
intervention group showed a significant increase after 
four days of intervention. We can point out that the 
extracted results of this study are consistent with the 
properties of Filgrastim (Neupogen). 
The effects of filgrastim on the complications 
of patients with cerebral haemorrhage due to positive 
trauma were evaluated, where it was positively 
effective. Because there is no serious complication on 
the days recommended, the use of this medication 
can be suggested. 
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